In addition, a novel recombinant adenovirus has been constructed that targeted E2F-1 and expressed IL-15, and validated its inhibitive effect on breast cancer cells, providing new experimental basis for breast cancer gene therapy. This evidence concerns the gene E2F1 and breast carcinoma.